{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:23:44Z","timestamp":1781623424603,"version":"3.54.5"},"reference-count":30,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There is no standard or widely effective treatment of patients with moderate aplastic anemia (MAA) or hypo-productive uni-lineage cytopenias (UC). Eltrombopag (EPAG), a small molecule thrombopoietin mimetic, has previously been shown to result in durable multi-lineage hematologic responses with low toxicity in patients with refractory severe aplastic anemia (SAA). Its safety and efficacy in MAA are unknown. This prospective phase 2 study enrolled previously untreated and treated MAA and UC patients with clinically relevant cytopenias. EPAG was administered at doses escalating from 50 to 300 mg\/d. Hematologic responses were assessed at 16 to 20 weeks. Responding patients were continued on EPAG until reaching defined robust or stable blood counts. EPAG was reinstituted for relapse. Thirty-four patients were enrolled between 2012 and 2017, including 31 with MAA and 3 with UC. Seventeen patients responded in at least 1 eligible lineage by the primary end point. A striking improvement in anemia was observed in a patient with Diamond-Blackfan anemia. EPAG was well tolerated, and it was discontinued for robust or stable blood counts in 12 of 17 patients after a median of 8 months. A majority required re-initiation of EPAG for declining counts, and all regained response. Two of 34 patients developed non\u2013chromosome 7 bone marrow cytogenetic abnormalities while taking EPAG, without dysplasia or increased blasts. Somatic mutation allele frequencies in cancer genes did not increase overall on EPAG. EPAG is a well-tolerated oral treatment of cytopenias in patients with MAA\/UC. This trial was registered at www.clinicaltrials.gov as #NCT01328587.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001657","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T15:40:55Z","timestamp":1587742855000},"page":"1700-1710","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7110-1242","authenticated-orcid":false,"given":"Xing","family":"Fan","sequence":"first","affiliation":[{"name":"Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Desmond","sequence":"first","affiliation":[{"name":"Tallaght University Hospital, Tallaght, Dublin, Ireland;"},{"name":"Hematology Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Winkler","sequence":"first","affiliation":[{"name":"Hematology Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-8568","authenticated-orcid":false,"given":"David J.","family":"Young","sequence":"first","affiliation":[{"name":"Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Dumitriu","sequence":"first","affiliation":[{"name":"Hematology Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Townsley","sequence":"first","affiliation":[{"name":"Hematology Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3116-4588","authenticated-orcid":false,"given":"Fernanda","family":"Gutierrez-Rodrigues","sequence":"first","affiliation":[{"name":"Hematology Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lotter","sequence":"first","affiliation":[{"name":"Office of the Clinical Director, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Valdez","sequence":"first","affiliation":[{"name":"Office of the Clinical Director, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Sellers","sequence":"first","affiliation":[{"name":"Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Evette","family":"Barranta","sequence":"first","affiliation":[{"name":"Office of the Clinical Director, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruba N.","family":"Shalhoub","sequence":"first","affiliation":[{"name":"Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin O.","family":"Wu","sequence":"first","affiliation":[{"name":"Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"first","affiliation":[{"name":"Genomics Testing Cooperative, Irvine, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Calvo","sequence":"first","affiliation":[{"name":"Hematology Section, Department of Laboratory Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal S.","family":"Young","sequence":"first","affiliation":[{"name":"Hematology Branch,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-838X","authenticated-orcid":false,"given":"Cynthia E.","family":"Dunbar","sequence":"first","affiliation":[{"name":"Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"issue":"1","key":"2020042811285653400_B1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2009.07842.x","article-title":"Guidelines for the diagnosis and management of aplastic anaemia","volume":"147","author":"Marsh","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2020042811285653400_B2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"2020042811285653400_B3","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1182\/blood-2003-04-1032","article-title":"Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia","volume":"102","author":"Maciejewski","year":"2003","journal-title":"Blood"},{"issue":"9","key":"2020042811285653400_B4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00277-013-1764-7","article-title":"A promising immunosuppressive strategy of cyclosporine alternately combined with levamisole is highly effective for moderate aplastic anemia","volume":"92","author":"Li","year":"2013","journal-title":"Ann Hematol"},{"issue":"7","key":"2020042811285653400_B5","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1182\/blood.V93.7.2191","article-title":"Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party","volume":"93","author":"Marsh","year":"1999","journal-title":"Blood"},{"issue":"5","key":"2020042811285653400_B6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s12185-010-0601-1","article-title":"Clinical course of non-severe aplastic anemia in adults","volume":"91","author":"Kwon","year":"2010","journal-title":"Int J Hematol"},{"issue":"5","key":"2020042811285653400_B7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/pbc.20131","article-title":"Natural history of moderate aplastic anemia in children","volume":"43","author":"Howard","year":"2004","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2020042811285653400_B8","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"108","author":"Young","year":"2006","journal-title":"Blood"},{"issue":"17","key":"2020042811285653400_B9","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra1413485","article-title":"Aplastic anemia","volume":"379","author":"Young","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2020042811285653400_B10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2020042811285653400_B11","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2020042811285653400_B12","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1182\/blood.2019000478","article-title":"Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag","volume":"133","author":"Winkler","year":"2019","journal-title":"Blood"},{"issue":"16","key":"2020042811285653400_B13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"2020042811285653400_B14","doi-asserted-by":"crossref","first-page":"e113747","DOI":"10.1371\/journal.pone.0113747","article-title":"Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans","volume":"9","author":"Gutierrez-Rodrigues","year":"2014","journal-title":"PLoS One"},{"issue":"6269","key":"2020042811285653400_B15","doi-asserted-by":"crossref","first-page":"aab2116","DOI":"10.1126\/science.aab2116","article-title":"Distinct routes of lineage development reshape the human blood hierarchy across ontogeny","volume":"351","author":"Notta","year":"2016","journal-title":"Science"},{"issue":"4","key":"2020042811285653400_B16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/ncb3493","article-title":"Human haematopoietic stem cell lineage commitment is a continuous process","volume":"19","author":"Velten","year":"2017","journal-title":"Nat Cell Biol"},{"issue":"11","key":"2020042811285653400_B17","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.3324\/haematol.2019.216374","article-title":"Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag","volume":"104","author":"Fattizzo","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"2020042811285653400_B18","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00277-019-03652-8","article-title":"Use of eltrombopag in aplastic anemia in Europe","volume":"98","author":"Ecsedi","year":"2019","journal-title":"Ann Hematol"},{"issue":"2","key":"2020042811285653400_B19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12185-019-02683-1","article-title":"Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy","volume":"110","author":"Yamazaki","year":"2019","journal-title":"Int J Hematol"},{"issue":"17","key":"2020042811285653400_B20","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2016-10-740241","article-title":"Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator","volume":"130","author":"Vlachodimitropoulou","year":"2017","journal-title":"Blood"},{"issue":"338","key":"2020042811285653400_B21","doi-asserted-by":"crossref","first-page":"338ra67","DOI":"10.1126\/scitranslmed.aaf3006","article-title":"Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome","volume":"8","author":"Yang","year":"2016","journal-title":"Sci Transl Med"},{"issue":"9","key":"2020042811285653400_B22","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V99.9.3129","article-title":"Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia","volume":"99","author":"Maciejewski","year":"2002","journal-title":"Blood"},{"issue":"458","key":"2020042811285653400_B23","doi-asserted-by":"crossref","first-page":"eaas9563","DOI":"10.1126\/scitranslmed.aas9563","article-title":"Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag","volume":"10","author":"Kao","year":"2018","journal-title":"Sci Transl Med"},{"key":"2020042811285653400_B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2019.03.002","article-title":"Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells","volume":"73","author":"Guenther","year":"2019","journal-title":"Exp Hematol"},{"issue":"1","key":"2020042811285653400_B25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.stem.2012.10.012","article-title":"Thrombopoietin-increased DNA-PK-dependent DNA repair limits hematopoietic stem and progenitor cell mutagenesis in response to DNA damage","volume":"12","author":"de Laval","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2020042811285653400_B26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2141.2000.01796.x","article-title":"Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia","volume":"108","author":"Giri","year":"2000","journal-title":"Br J Haematol"},{"issue":"21","key":"2020042811285653400_B27","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2018-01-826784","article-title":"Eltrombopag mobilizes iron in patients with aplastic anemia [published correction appears in Blood. 2018;132(4):459]","volume":"131","author":"Zhao","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2020042811285653400_B28","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2017-12-822262","article-title":"The enigma of monosomy 7","volume":"131","author":"Inaba","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2020042811285653400_B29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"2020042811285653400_B30","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/8\/1700\/1725489\/advancesadv2020001657.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/8\/1700\/1725489\/advancesadv2020001657.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T15:30:55Z","timestamp":1588087855000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/8\/1700\/454469\/Eltrombopag-for-patients-with-moderate-aplastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001657","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]}}}